Galectin Therapeutics (NASDAQ:GALT) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Galectin Therapeutics (NASDAQ:GALT) in a research report released on Friday, Benzinga reports. The firm currently has a $11.00 price objective on the stock. HC Wainwright also issued estimates for Galectin Therapeutics’ Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.53) EPS and FY2027 earnings at $1.29 EPS.

Separately, StockNews.com cut shares of Galectin Therapeutics from a hold rating to a sell rating in a research report on Thursday, July 18th.

Galectin Therapeutics Trading Up 1.3 %

NASDAQ GALT opened at $2.35 on Friday. Galectin Therapeutics has a 12 month low of $1.55 and a 12 month high of $4.27. The stock has a 50-day simple moving average of $2.34 and a 200 day simple moving average of $2.54. The company has a market capitalization of $146.05 million, a PE ratio of -3.18 and a beta of 0.63.

Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04). As a group, sell-side analysts predict that Galectin Therapeutics will post -0.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Marshall Wace LLP acquired a new stake in Galectin Therapeutics during the 2nd quarter valued at $43,000. Rhumbline Advisers acquired a new stake in shares of Galectin Therapeutics during the 2nd quarter worth about $44,000. Retirement Guys Formula LLC boosted its holdings in shares of Galectin Therapeutics by 56.9% during the 1st quarter. Retirement Guys Formula LLC now owns 33,732 shares of the company’s stock worth $81,000 after buying an additional 12,232 shares during the period. Solutions 4 Wealth Ltd acquired a new position in Galectin Therapeutics in the 4th quarter valued at about $60,000. Finally, Traynor Capital Management Inc. raised its holdings in Galectin Therapeutics by 23.5% in the 2nd quarter. Traynor Capital Management Inc. now owns 42,871 shares of the company’s stock valued at $97,000 after acquiring an additional 8,164 shares during the period. 11.68% of the stock is currently owned by institutional investors and hedge funds.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.